Futibatinib is the most advanced candidate in the category of covalent pan-FGFR inhibitors because it is in phase 3 clinical trial to evaluate the treatment of metastatic and recurrent unresectable cholangiocarcinoma harboring FGFR2 gene rearrangements. The gene discussed is FGFR2; the disease is cholangiocarcinoma.